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ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) SEVERE
APLASTIC ANEMIA, A SINGLE CENTER EXPERIENCE IN BOGOTA,
COLOMBIA
Abello, V., Villamizar, L., Pedraza, E., Esguerra, H., Rosales, C.,
Linares, A., Rosales, M., Figueroa, J., Mantilla, W. Clınica de Marly,
Bogota, Colombia
Allo-SCT from an HLA related or unrelated donor is the first line
treatment for newly diagnosed patients with BMFS younger than 40
years, and for older patients that failed immunosuppressive therapy.
Cohort retrospective analysis of BMFS patients receiving Allo-SCT
in a mixed (pediatric-adult) transplant center in Bogota, Colombia,
are reported.
Log-rank tests(Lrt) analyses were used to determine the effects of
age, conditioning regimen and year of treatment on survival.
Between January 1993 and August 2011, 74 transplants were per-
formed in 70 patients(52 acquired SAA,16 Fanconi Anemia and 2
pure red cell aplasia). Table 1 reflects patients and transplant charac-
teristics. 70 grafts were obtained fromHLA identical siblings, 3 from
unrelated CBU and 1 from a haploidentical sibling. Conditioning
regimens used were: RIC Cy-Flu-ATG(22), Cy-ATG(33) and
Cy(12). 4 patients were conditioned with Campath containing regi-
mens and 3 with other. Before 2004 most patients received Cs and
MTX as GVHD prophylaxis, after 2004 Cs and MMF was used in
the majority.
Table 1. Patients and transplant characteristicsGender, n M/F 42/28
Age, years mean (range) 25.5 (4 - 60)
Time from diagnosis to transplant,
months mean (range)
26.4 (2.1 - 143)More than 10 transfusions before
transplant, n Y/N41/26 (3 not known)Stem cell source n (BM/PBSC/CBU) 6/65/3
Hospital stay, days mean (range) 29.9 (16-94)
CD34+ x 10-6 infused mean (range) 3.7 (0.3-17)*
PMN graft, days mean (range) 11.5 (7-21)**Excluding CBUT
One 13 year old patient, expired before stem cell infusion due to sepsis.
For the first transplant 68 patients engrafted, average at 11.5 days with-
out significant differences between conditioning regimens. 3 patients (1
Cy-ATG, 1 Campath based, 1 Cy-Flu-ATG) had secondary graft failure
and were successfully transplanted with PBSC of the same donor. One
patient had a primary graft failure after a CBTand was successfully trans-
planted with PBSC from a haploidentical sibling. Four patients with graft
failure are alive.
Non-myeloablative conditioning containing Fludarabine, re-
sulted in less hospital stay compared to Cy-ATG and Cy alone
(22.9, 32, 33 days respectively), less fever (1.7, 6.7, 7 days), less par-
enteral nutrition (0.1, 9, 4 days) and less red cells (2.4, 3.8, 3.8) and
platelet (4.5, 7.5, 9.75) transfusions.
The median follow-up was 18.4 months (range: 4.3- 45.3). Five-
year overall survival (OS) was 70.5%; 94% for Flu-Cy-ATG; 75%
for Cy-ATG and 30%Cy (p5 0.0008). There was no significant dif-
ference in survival related to age (less than 40 years (n5 53) 73,3% vs
over 40 years (n 5 15) 69.9%, p 5 0.67). There as superior survival
for transplants performed before 2004 (n5 18) compared with those
after (n 5 50) (51% vs 78%, p 5 0.38).
This experience shows excellent survival for Allo-SCT in patients
with BMFS regardless the age, demonstrating advantage of Flu based
RIC over other conditioning regimens.
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FIVE VERSUS 2.5 MG/KG OF ANTI-THYMOCYTE-GLOBULIN DOSE IN RE-
DUCED-INTENSITY-CONDITIONING REDUCES ACUTE AND CHRONIC
GRAFT-VERSUS-HOST DISEASE FOR PATIENTS WITH MYELOID MALIG-
NANCIES UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
Devillier, R., Crocchiolo, R., Castagna, L., F€urst, S., El Cheikh, J.,
Faucher, C., Prebet, T., Etienne, A., Chabannon, C., Esterni, B.,
Blaise, D. Institut Paoli Calmettes, Marseille, FranceReduced intensity conditioning (RIC) regimen with Fludarabine,
Busulfan and 2.5 mg/kg of anti-thymocyte globulin (r-ATG) was
previously reported to be effective but with a high rate of acute
and chronic graft-versus-host disease (GVHD). So we increased
r-ATG dose from 2.5 mg/kg to 5 mg/kg days. We analyzed 87 pa-
tients with acute myeloid leukemia (AML) or myelodysplastic syn-
drome (MDS) undergoing Allo-SCT from an HLA-identical
sibling donor from 2000 to 2010. RIC consisted of Fludarabine,
Busulfan and r-ATG 2.5 mg/kg 1 day (r-ATG1; n 5 53) or 2.5
mg/kg/day over 2 days (r-ATG2; n 5 22). Grade 2-4 acute
GVHD incidence at day 100 was 30.2% and 8.8% in the r-
ATG1 and r-ATG2 groups respectively (p 5 0.038). Extensive
chronic GVHD incidence was 60.4% and 12% in the r-ATG1
and r-ATG2 groups respectively (p\0.001). The relapse incidence
(RI) at 24 months was 21.7%. r-ATG dose was not significantly as-
sociated with higher RI (18.9% and 28.5% in r-ATG1 and r-ATG2
groups respectively (p 5 0.640)). Overall and progression free sur-
vival were not different between the r-ATG1 and r-ATG2 groups.
r-ATG dose at 5 mg/kg in the setting of RIC seems a good balance
allowing GVHD prevention and antitumor effect with a dramatic
reduction of chronic GVHD incidence without increasing signifi-
cantly the relapse rate.362
PROSPECTIVE TRIAL OF PRE-TRANSPLANT 5-AZACITIDINE ON HEMATO-
POIETIC CELL TRANSPLANTATION OUTCOMES FOR MYELODYSPLASTIC
SYNDROME AND CMML
Field, T.1, Perkins, J.1, Nishori, T.1, Pidala, J.1, Fernandez, H.F.1,
Tomblyn, M.1, Kharfan-Dabaja, M.1, Perez, L.1, Komrokji, R.S.2,
Lancet, J.2, Kim, J.3, Ayala, E.1, Alsina, M.1, Ochoa-Bayona, J.-L.1,
Locke, F.1, Betts, B.1, List, A.2, Anasetti, C.1 1H. LeeMoffitt Cancer Cen-
ter, Tampa, FL; 2H. Lee Moffitt Cancer Center, Tampa, FL; 3H. Lee
Moffitt Cancer Center, Tampa, FL
We report the results of a prospective clinical trial with the ob-
jective of evaluating HCT outcomes following pre-HCT therapy
with 5-azacitidine. Twenty-five patients seen in consultation for
HCT and medically eligible for a donor search were enrolled and
received 5-azacitidine [75mg/m2 for 7 days every 4 weeks] until
a suitable donor was identified. Four did not proceed to transplant
for the following reasons: failure to obtain insurance approval due
to patient age, failure of the pre-HCT organ evaluation although
a donor was identified, CNS hemorrhage in setting of chronic
anti-coagulation five days prior to HCT admission and one de-
clined HCT as only a HLA-A mismatched donor was available.
Twenty-one patients received a HCT following a myeloablative
targeted busulfan fludarabine regimen. Median age at HCT was
57 years (25 - 67). IPSS at diagnosis was Int-1 (3), Int2 (10) and
high (5), CMML1 (1), AMLM6 (1) and not evaluable (NE) (1).
Cytogenetic risk was good (9), intermediate (5) and poor (8).
Four patients had therapy related MDS. Patients received a median
of 4 (1-6) cycles of 5-azacitidine. Median time from diagnosis (or
time of progression in 2 patients) to HCT infusion was 198 days
(107 - 350). Response to 5-azacitidine prior to HCT by the Inter-
national Working Group 2006 criteria included partial response (8),
stable disease (9) and 4 progressed. Three received leukemic induc-
tion chemotherapy prior to HCT. IPSS score prior to HCT was
Low (1) Int-1 (6), Int2 (10) and high (1), CMML1 (2) and NE
(1). Patients received peripheral blood stem cells from siblings
(8), matched unrelated donors (11) and mismatch unrelated donors
(2). Median follow-up for survivors is 28.3 months (9.6-37.2
months). Five patients did not achieve remission (1) or relapsed
(4) and 1 of the five remains alive. There are 6 non-relapse deaths,
4 due to infection and 2 due to GVHD. Two year cumulative inci-
dences of nonrelapse mortality and relapse from time of transplant
are 30% (95% confidence interval [CI] 15%-59%) and 24% (95%
CI 11%-51%). At two years OS is 50% (95% CI 28%-72%) and
DFS is 46% (95% CI 24%-68%). In conclusion, pre-HCT 5-aza-
citidine was well tolerated, provided control of disease as a bridge
to HCT and did not impose additional toxicity after allogeneic
HCT with a promising 2 year disease free survival. Controlled trials
are needed to determine whether post-transplant relapse and sur-
vival are improved by pre-transplant 5-azacitidine.
